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Abstract
Background Self-efficacy beliefs are an important determi-
nant of (changes in) health behaviors. In the area of smoking
cessation, there is a need for a short, feasible, and validated
questionnaire measuring self-efficacy beliefs regarding
smoking cessation.
Purpose The purpose of this study is to investigate the
psychometric properties of a six-item questionnaire to assess
smoking cessation self-efficacy.
Methods We used longitudinal data from a smoking cessa-
tion study. A total of 513 smokers completed the Smoking
Abstinence Self-efficacy Questionnaire (SASEQ) and ques-
tionnaires assessing depressive symptoms and motivation to
quit smoking. After that, they set a quit date and attempted
to stop smoking. One year after the quit date, smoking status
of participants was assessed by self report. The psychomet-
ric properties of the SASEQ were studied and we investi-
gated whether SASEQ scores predicted successful smoking
cessation.
Results Factor analysis yielded one factor, with an Eigen-
value of 3.83, explaining 64% of variance. All factor load-
ings were ≥0.73. We found a Cronbach’s alpha of 0.89 for
the SASEQ, low correlations for the SASEQ with depres-
sive symptoms, and motivation to quit, indicating that self-
efficacy is measured independently of these concepts. Fur-
thermore, high baseline SASEQ scores significantly pre-
dicted smoking abstinence at 52 weeks after the quit date
(OR01.85; 95% CI01.20~2.84).
Conclusions The SASEQ appeared to be a short, reliable,
and valid questionnaire to assess self-efficacy beliefs regard-
ing smoking abstinence. In the present study, this instrument
also had good predictive validity. The short SASEQ can
easily be used in busy clinical practice to guide smoking
cessation interventions.
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Introduction
Self-efficacy is defined as the confidence a person has in his
or her ability to perform and sustain a certain behavior in a
given situation [1, 2]. It is an important component of
several theories of behavior change. Efficacy expectations
are proposed to be better predictors of behavior than are
previous or current behaviors alone [3]. Self-efficacy
depends on past experience with the behavior, influence of
others, physiological state, and outcome expectations [4].
The concept of self-efficacy is particularly relevant for
smoking cessation. People with a high confidence in their
ability to quit smoking are more often successful in smoking
cessation [5–7] and relapse less often after a quit attempt [8].
As self-efficacy is an important psychological construct
with immediate relevancy and practical implications to
smoking cessation, it is useful to measure it in routine
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clinical practice, for example in pregnant women or in heart
patients.
In the past, various questionnaires to measure self-
efficacy with regard to smoking cessation have been used
[8–15]. These questionnaires generally consist of a list of
smoking situations for which respondents can rate their
confidence in their ability to refrain from smoking [16].
However, these instruments are not always feasible for use
in routine clinical care as they are composed of twelve to 48
items. Therefore, a new, six-item self-efficacy scale was
constructed: the Smoking Abstinence Self-efficacy Ques-
tionnaire (SASEQ).
In the current study, we investigate the psychometric
properties of this six-item self-efficacy scale in a prospective
smoking-cessation trial.
As self-efficacy may be influenced by motivation to quit
smoking and depression [17–20], we investigated the asso-
ciation of self-efficacy with measures of motivation and
depression. Self-efficacy is a separate concept from depres-
sion and motivation to quit smoking, so we hypothesized
that correlations between these concepts would be low.
Furthermore, we hypothesized that high scores on the




Between January 2004 and January 2007, 513 smokers
participated in a smoking cessation program (STOPPERS).
They were recruited by general practitioners of 15 general
practices and specialists of the two departments of Máxima
Medical Centre hospital in Eindhoven and Veldhoven. The
inclusion criteria were willingness to discuss smoking be-
havior and sufficient understanding of the Dutch language.
The only exclusion criterion was any participant suffering
from a severe psychiatric disorder in immediate need of
treatment.
Procedure
All smokers received smoking cessation advice from
their general practitioner or medical specialist. When
patients showed interest in smoking cessation, they were
referred to the study project. All participants were from
Eindhoven and its surrounding areas, in the South East
of the Netherlands. They all signed informed consent
forms. The study protocol was approved by the Maxima
Medical Centre ethics committee, which is certified by the
Central Committee on Research involving Human Subjects in
the Netherlands.
Participants were asked to complete several question-
naires. The quit date was set usually approximately 4 weeks
after the inclusion in the study. Fifty-two weeks after the
quit date, smoking status was assessed.
Measures
Smoking Abstinence Self-efficacy Questionnaire
The SASEQ was constructed based on extensive experience
with smoking cessation interventions and knowledge of the
literature [8, 14, 15, 21–26]. The eight-item self-efficacy
subscale as developed by Dijkstra, de Vries, and Roijackers
[24] was used as a basic and further refined. It consists of
two dimensions: four items describing “social” situations
and four items describing “emotional” situations. Based on
face validity two items were removed, one item: “going out
with friends,” because it describes more or less the same
situation as in the item: “being in a café or at a party,” and
another emotional item (“feeling bored”) because it is quite
different from the other emotional items: agitated, angry,
and sad [24]. The remaining six items describe situations for
which smokers can indicate on a 5-point Likert scale (0–4)
whether they will be able not to smoke (Appendix I).
The higher the score, the higher the level of self-efficacy
regarding smoking cessation is. The range of the SASEQ scale
is 0–24.
Edinburgh Depression Scale
The Edinburgh Depression Scale (EDS) [27–30] is a ten-
item self-report scale which measures depressive symp-
toms. Respondents can rate on a 4-point Likert scale
(0–3) to what extent they have had depressive feelings
and thoughts over the past 7 days. The higher the score,
the more depressive symptoms the respondent has. The
range of the EDS is 0–30.
Symptom Checklist List-90 anxiety subscale
Anxiety was assessed by means of the anxiety subscale of
the Symptom Checklist List-90 (SCL-90). The SCL-90 is
used to assess psychopathology and has extensively been
validated in the Netherlands [31]. The anxiety subscale
consists of ten items that can be rated on a 5-point Likert
scale [1–5]. The higher the score, the more anxious the
respondent is. The range of the anxiety subscale is 10–60.
Int.J. Behav. Med. (2013) 20:444–449 445
Motivation to Quit Smoking
Motivation to quit smoking was assessed with the following
question “How motivated are you to quit smoking com-
pletely?” This question is derived from questionnaires of
the MAYO Clinics in the USA. Respondents were presented
with a 5-point Likert scale: (0) not at all motivated, (1) not
very motivated, (2) neutral, (3) a little motivated, and (4) very
motivated.
Demographic characteristics of the participants and
smoking habits were also registered.
Smoking Status
Smoking status was assessed by self-report. At 52 weeks
after the quit date, participants were asked if they had
smoked since the original date of quitting. Long-term absti-
nence was defined as abstinence for at least 6 months. When
participants did not provide follow-up data, we assumed
they had started smoking again.
Analyses
Explorative factor analysis was used to identify the under-
lying factors of the questionnaire. We used the principal axis
factoring method with Varimax rotation. Prior to this anal-
ysis, the Kaiser–Meyer–Olkin measure of sampling adequa-
cy and the Bartlett’s test of sphericity were examined to
evaluate whether the data fulfilled the assumptions for car-
rying out a factor analysis. The Kaiser–Guttman criterion
(eigenvalue>1) was utilized to decide on the number of
factors retained. Homogeneity of factor solution(s) was de-
termined by calculating item-total correlations and internal
consistency by Cronbach’s alpha. An alpha of ≥0.7 was
regarded as sufficient [32].
The discriminant validity of the SASEQ was investigated
by calculating Pearson correlations with the SCL anxiety
subscale, the EDS, and motivation to quit smoking.
To determine the predictive validity of the SASEQ scale
as a predictor of successful smoking cessation, we used
logistic regression analysis. Successful smoking cessation
was defined as not having smoked for the past six months.
In the regression analysis, we also included known predic-
tors for smoking cessation [33] in order to determine the role
of the SASEQ score. We included the following predictors:
gender, duration of longest quit attempt, smoking status of
partner, average number of cigarettes per day, and duration
of being a smoker. We also conducted a t test to see whether
people who had achieved long-term abstinence at 52 weeks,
scored higher on the SASEQ at baseline.
Results
Participants
Demographic characteristics are summarized in Table 1. The
sample consisted of 52% women. The mean age was 51 years
(SD011). Most participants had completed medium level edu-
cation and were married or living with a partner. They smoked
on average 20 cigarettes/day (SD010). The mean age when
they smoked their first cigarette was 15 (SD03.35), and the
mean age when they started smoking daily was 17 (SD04.19).
Participants had undertaken on average 3.6 quit attempts (SD0
4.24). The average score on the item regarding their motivation
to quit smokingwas 3.4 (SD00.9); themean SASEQ score was
11.7 (SD05.5).
Factor Analysis
The Kaiser–Meyer–Olkin measure (0.86) and Bartlett’s test of
sphericity (p<0.001) indicated that the assumptions for factor
analysis were met. Exploratory factor analysis yielded one
factor (eigenvalue>1), with an eigenvalue of 3.8, explaining
64% of the variance. The second factor had an eigenvalue of
0.79; therefore, it is not taken into account. All factor loadings
were ≥0.73 (Table 2). The factor structure was the same for
men and women and across different educational levels.
Internal Consistency
The internal consistency of the SASEQ was good, we found
a Cronbach’s alpha of 0.89, and if items were deleted,









Married/living with partner 73.7%
Single 26.3%
Number of cigarettes/day 19.74 (10.17) 1–85
Age of first cigarette 15 (3.35) 6–40
Age when started smoking daily 17 (4.19) 10–50
Number of previous quit attempts 3.60 (4.24) 0–40
SASEQ total score 11.74 (5.48) 0–24
Depression 6.30 (5.20) 0–25
Motivation to quit 3.41 (0.84) 0–4
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Cronbach’s alpha decreased. Item-total correlations for
items 1–6 ranged between 0.68 and 0.73.
Discriminant and Predictive Validity
We found significant very low and negative correlations for
the SASEQ with the EDS depression score (r0−0.145; p0
0.001). Furthermore, we found a low, positive, significant
correlation for the SASEQ with motivation to quit (r00.205;
p<0.001).
The logistic regression analysis was conducted with
smoking status as the dependent variable, and with self-
efficacy, gender, duration of longest quit attempt, smoking
status of partner, average number of cigarettes per day, and
duration of being a smoker as covariates.
We found that only the SASEQ score significantly
predicted smoking status at 52 weeks after the quit date.
Participants with higher scores on self-efficacy were
significantly less likely to start smoking again (OR0
0.95; 95% CI00.91~0.99; p00.02). We also conducted
a t test to see whether people who had achieved long-
term abstinence at 52 weeks, scored higher on the SASEQ.
We found that non-smokers at 52 weeks indeed had signifi-
cantly higher SASEQ self-efficacy scores (t02.68; df0511;
p00.008): the mean SASEQ score for smokers was 11.41
(SD05.41); whereas the mean SASEQ score for non-
smokers was 13.00 (SD05.60).
Discussion
This study investigated the psychometric properties of a six-
item self-efficacy scale for smoking abstinence. Factor
analysis of the SASEQ showed one factor with an
explained variance of 64%. All factor loadings were
adequate. The SASEQ had high internal consistency
(Cronbach’s alpha00.89) and good discriminant validity.
We found a significant, very low, negative correlation
for the SASEQ with depression, and a significant, low,
positive correlation with motivation to quit smoking.
These findings support the disciriminant validity of SASEQ,
indicating that this instrument does not measure depres-
sion or motivation to quit smoking, and confirms that
self-efficacy is indeed a separate concept from these two
concepts.
To investigate the predictive validity of the SASEQ, we
analyzed whether our respondents' SASEQ scores predicted
smoking status. We found that the SASEQ score before the
planned quit date significantly predicted smoking abstinence at
52 weeks after the quit date. The odds ratio of 1.85 indicates
that people who score high on the SASEQ, have a much higher
chance to abstain from smoking, compared with people who
score low on the SASEQ (95% CI01.20~2.84). Furthermore,
we found that non-smokers at 52 weeks had rated themselves
significantly higher on self-efficacy before quitting.
Our results indicate that the SASEQ is a very good ques-
tionnaire for use in a clinical setting. It is psychometrically
sound and very short: with only six items, it can be easily
completed in a waiting-room, or incorporated in a larger ques-
tionnaire booklet without adding too many extra questions. It
should be noticed that in the Netherlands, nowadays, quit
smoking strategies have been implemented in large chronic
health care programs (diabetes, cardiovascular risk manage-
ment, and COPD), managed by GP nurses in Primary Care
[34]. Unfortunately, within these health care programs and in
contrast to the assessment of concepts as depression and anx-
iety, appropriate instruments are lacking to detect the patient’s
characteristics with regard to capability of changing behavior.
This is not only important for quit smoking strategies but also
in motivating diabetics for improving daily activities or obese
patients to change their eating behavior. Because the GP
nurse is often confronted with chronic patients with a
high degree of co-morbidity and the outpatient clinic
consultation time is limited, short instruments are need-
ed which can easily be used in daily practice. Moreover,
when reliable instruments do exist which are able to discrim-
inate between patients with high and low self-efficacy, it might
be speculated that—in view of cost-effectiveness—in the
future different programs of different intensity can be offered
to different patients.
A limitation of the study is that there were no other self-
efficacy measures available to correlate the SASEQ score
with, in order to assess convergent validity. Another limitation
is the fact that motivation to quit smoking was measured with
one item, instead of making use of a questionnaire. Strong
points of the study are the prospective design and the large
sample size.
In conclusion, the SASEQ seems to be an instrument that
can assess self-efficacy regarding smoking abstinence reli-
ably and validly. SASEQ scores appeared to be significant
predictors of successful smoking cessation. We would like
to emphasize that this six-item questionnaire can be completed
in approximately 1 min and is therefore feasible for use in
busy clinical practice.
Table 2 Factor loadings of SASEQ
Loading
You feel agitated or tense 0.74
You are (very) angry 0.73
You are in a café, at a party, or paying a visit 0.79
You feel (very) sad 0.78
Someone offers you a cigarette of your own brand 0.74
You see someone enjoy smoking 0.75
Eigenvalue, 3.83 and percentage of explained variance, 63.86
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Appendix 1: The Smoking Abstinence Self-efficacy
Questionnaire (SASEQ)




□ Neutral / don’t know
□ Probably not
□ Certainly not







3. You are in a café, at a party, or paying a visit. Are you













5. Someone offers you a cigarette of your own brand. Are






6. You see someone enjoy smoking. Are you confident
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